Pfizer (NYSE:PFE) has been given a $39.00 price objective by equities research analysts at BMO Capital Markets in a report issued on Friday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target would indicate a potential upside of 9.86% from the company’s current price.

PFE has been the subject of several other research reports. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. J P Morgan Chase & Co set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, November 1st. Jefferies Group set a $39.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Thursday, November 16th. Berenberg Bank set a $36.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, October 31st. Finally, Morgan Stanley upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company’s stock. Pfizer has a consensus rating of “Buy” and an average target price of $38.77.

Pfizer (NYSE PFE) traded down $0.06 during trading on Friday, hitting $35.50. 15,807,700 shares of the stock traded hands, compared to its average volume of 19,960,639. The firm has a market capitalization of $211,962.75, a PE ratio of 14.22, a PEG ratio of 2.51 and a beta of 1.01. Pfizer has a 12 month low of $30.51 and a 12 month high of $36.78. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.61 earnings per share. equities research analysts forecast that Pfizer will post 2.59 EPS for the current fiscal year.

In other news, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now directly owns 117,432 shares of the company’s stock, valued at $4,145,349.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $35.65, for a total transaction of $262,027.50. Following the completion of the transaction, the executive vice president now directly owns 117,432 shares in the company, valued at $4,186,450.80. The disclosure for this sale can be found here. Insiders sold 60,280 shares of company stock worth $2,118,988 over the last three months. Insiders own 0.06% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Shine Investment Advisory Services Inc. acquired a new stake in shares of Pfizer in the 2nd quarter valued at approximately $102,000. Mckinley Capital Management LLC Delaware acquired a new stake in shares of Pfizer in the 2nd quarter valued at approximately $103,000. D. Scott Neal Inc. boosted its position in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC acquired a new stake in Pfizer during the 1st quarter worth approximately $121,000. Finally, Herndon Capital Management LLC acquired a new stake in Pfizer during the 2nd quarter worth approximately $120,000. 69.89% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/08/pfizer-pfe-given-a-39-00-price-target-at-bmo-capital-markets.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.